試す - 無料

Miran’ monetary policy advocacy is simply puzzling

Mint Mumbai

|

September 25, 2025

Through one of the strangest twists in economic history, Stephen Miran, chief economic advisor to US President Donald Trump and newly appointed member of the Federal Reserve's board of governors, hasseen his career resurrected in almost mythical fashion ever since the failure ofthe investment firm he co-founded in 2022.

- RAHUL JACOB

That company, Amberwave Partners, launched an ETF that “never attracted more than $1.7 million in assets” (a trifling sum in the world of US money management), according to The Wall Street Journal. Amberwave morphed into a hedge fund but didn’t gain traction and shut in late 2023.

Scarcely a year later, Trump’s victory in the US election amounted to a rebirth for Miran. Apart from being among the most ardent ofall the president’s yes-men, he isa vocal proponent of drastically curbing immigration, weakening the dollarand asking US allies to bear a larger share of defence expenses on strategic alliances. Trump’swin paved the way for him to take up a much larger roleas chair of the US Council of Economic Advisers. Last week, the 42-year-old economist, newly appointed to the Fed by a slim Senate margin, with every Democratic senator having voted against his appointment, cast the lone dissenting vote in the Fed’smonetary policy decision. He wanted a 50-basis-point cut to the Fed's federal funds target, twice the size of what was delivered. On Monday, Miran doubled down, arguing that the US economy needsaggressive cutsso the policy rate reaches about 2.5%.

Mint Mumbai からのその他のストーリー

Mint Mumbai

Mint Mumbai

Gen Alpha will make new rules for their workplace

Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’

time to read

3 mins

December 01, 2025

Mint Mumbai

EC extends electoral roll revision by a week to II Dec; final list on 14 Feb

The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.

time to read

2 mins

December 01, 2025

Mint Mumbai

THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS

These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.

time to read

3 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

Green hydrogen: Fast fashion could help bump up demand

A boom in its use for clean synthetic inputs might make a difference

time to read

3 mins

December 01, 2025

Mint Mumbai

Let's be a bit more selective in using the word 'reforms'

Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.

time to read

3 mins

December 01, 2025

Mint Mumbai

As mid-cap alpha shrinks, should you consider passive strategies?

Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey

time to read

4 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

With $2.2 bn fund, ChrysCap has appetite for riskier bets

MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing

time to read

3 mins

December 01, 2025

Mint Mumbai

GDP growth of 8% plus: How to sustain this pace

Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships

time to read

2 mins

December 01, 2025

Mint Mumbai

INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES

Detection tools today are not universal or consistent across languages

time to read

5 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

APIs to innovation: Bulk drug makers ramp up CDMO bets

Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.

time to read

2 mins

December 01, 2025

Listen

Translate

Share

-
+

Change font size